期刊文献+

凡德他尼的合成工艺研究

Study on Synthetic Process of Vandetanib
下载PDF
导出
摘要 目的:提供一条合成凡德他尼新工艺路线。方法:以香兰素为起始原料,经过酚羟基苄基保护、氧化、硝化、还原、环合和氯代反应得到7-苄氧基-4-氯-6-甲氧基喹唑啉,再与2-氟-4-溴苯胺发生取代反应,然后脱苄基生成4-(2-氟-4-溴苯胺基)-6-甲氧基-7-羟基喹唑啉(10),收率33.1%;以4-哌啶甲酸乙酯为原料,经Leuckart N-甲基化反应、酯基还原反应,然后和对甲苯磺酰氯反应生成磺酸酯(14),收率35.1%。最后将(10)和(14)在碱性条件下缩合得到目标产物凡德他尼(1)。(1)的总收率11.6% (以化合物(2)和(11)计)。结果:目标化合物及其中间体的化学结构都经过IR、1H-NMR和HR-MS图谱确证。结论:本方法缩短了反应步骤,反应条件温和、操作简便。 Objective: To develop a new synthetic route for Vandetanib. Methods: 4-(2-fluoro-4-bromo-ami- no)-6-methoxy-7-hydroxy-quinazoline (10) was prepared from vanillin (2) via phenolic hydroxyl protection, oxidation, nitration, reduction, cyclization and chlorination to afford 7-benzyloxy-4- chloro-6-methoxy-quinazoline (7), and then (7) coupled with 2-fluoro-4-bromoaniline, followed by debenzylation, yield 33.1%. (1-methylpiperidin-4-yl)methyl 4-methylbenzenesulfonate (14) was prepared from ethyl piperidine-4-carboxylate(11) by Leuckart reaction, reduction and then reacted with p-toluenesulfonyl chloride, yielding 35.1%. In addition, 10 was reacted with 14 to yield the antitumor drug vandetanib (1) with an overall yield of 11.6% (based on compound 2 and 11). Results: The structure of all products was confirmed by IR, 1H-NMR and HR-MS. Conclusion: The improved process has several advantages over those reported procedures, such as brief reac-tion steps, mild conditions, and simple operations.
出处 《合成化学研究》 2015年第2期28-34,共7页 Studies in Synthetic Chemistry
  • 相关文献

参考文献3

二级参考文献47

  • 1Antonello A, Tarozzi A, Morroni F, Cavalli A, Rosini M, Hrelia P, et al. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J Med Chem 2006; 49: 6642-5.
  • 2Fry DW, Kraker A J, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. Specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093-5.
  • 3Ward WHJ, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48: 659-66.
  • 4Rusnak DW, Lackey K, Affteck K, Wood ER, Alligood K J, Rhodes N, et al. The effects Of the novel, reversible epidermal growth factor receptor/erbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
  • 5Domarkas J, Dudouit F, Wiliiams C, Qiyu Q, Banerjee R, Brahimi F, et al. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006; 49: 3544-52.
  • 6Mishani E, Abourbeh G, Jacobson O, Dissoki S, Daniel RB, Rozen Y, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-irnaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005; 48: 5337-48.
  • 7Rewcasfle GW, Palmer BD, Thompson AM, Bridges A J, Cody DR, Zhou H, et al. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromo- phenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem 1996; 39: 1823-35.
  • 8Rewcastle GW, Bridges A J, Fry DW, Rubin JR, Denny WA. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J Med Chem 1997: 40: 1820-6.
  • 9Norman MH, Kelly JL, Hollingsworth EB. Conformationally restricted analogues ofremoxipride as potential antipsychotic agents. J Med Chem 1993; 36: 3417-23.
  • 10Hodge CN, Pierce J. A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase. Bioorg Med Chem Lett 1993; 3: 1605-8.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部